로딩 중…
StockDiggingStockDigging

SAMIL PHARMACEUTICAL CO.,LTD

000520· KOSPI
₩6,910-1.99%
2026-06-19

Price Chart

SAMIL PHARMACEUTICAL CO.,LTD-31.65%

Financials

Investment Metrics(as of 2026-06-19)

MetricValue
Size
Market Cap149.89B KRW
Revenue210.51B KRW
Net Income-36.42B KRW
Total Assets372.34B KRW
Net Assets128.56B KRW
Employees593
Value
P/B1.17x
P/S0.71x
FCF Yield-4.60%
Profitability
ROE-28.33%
ROA-9.78%
Op. Margin-5.50%
Revenue Growth0.50%
Financial Health
Debt Ratio189.63%
Total Debt163.89B KRW
FCF-6.89B KRW
Cash1.19B KRW
Current Ratio0.46x
Performance
1Y Return-31.65%
1M Return-11.86%
From 52W High-46.27%
1Y MDD-45.12%
Trading
Volume127,584 shares
Foreign Own.3.85%
Per Share
EPS-1,679 KRW
BPS6,016 KRW

Company Info

CEO 허승범
Employees 593
Founded 1947
HQ 서울특별시 서초구, KR

Samil Pharmaceutical, a mid-sized pharmaceutical company established in 1947 and listed on KOSPI in 1985, primarily develops, produces, and sells specialized and generic pharmaceuticals. The company also exclusively distributes directly imported original products in Korea. It operates a subsidiary with a global ophthalmic CDMO factory in Vietnam and has secured domestic sales rights for new drugs from Galmed and Biosplice. Samil Pharmaceutical is pursuing growth in new drug development and global CDMO business, headquartered in Seocho-gu, Seoul.